Our results include well-characterized regulators of plasma lipoprotein metabolism that are existing drug targets for coronary artery disease (e.g., PCSK9), as well as experimentally uncharacterized targets that have not been directly linked to coronary artery disease (e.g., endotrophin, PPCS, and HTRA1).53 Here, PCSK9 is linked to coronary artery disorder.